Angiotensin II Receptor Blockers Differentially Affect CYP11B2 Expression in Human Adrenal H295R Cells.

Ken Matsuda,Akira Uruno,Naotaka Kogure,Kaori Sugawara,Hiroki Shimada,Masahiro Nezu,Takako Saito-Ito,Yuko Iki,Masataka Kudo,Kyoko Shimizu,Ikuko Sato,Takeo Yoshikawa,Fumitoshi Satoh,Ryo Ito,Atsushi Yokoyama,William E. Rainey,Akiko Saito-Hakoda,Sadayoshi Ito,Akira Sugawara
DOI: https://doi.org/10.1016/j.mce.2013.12.004
IF: 4.369
2014-01-01
Molecular and Cellular Endocrinology
Abstract:We generated a stable H295R cell line expressing aldosterone synthase gene (CYP11B2) promoter/luciferase chimeric reporter construct that is highly sensitive to angiotensin II (AII) and potassium, and defined AII receptor blocker (ARB) effects. In the presence of AII, all ARBs suppressed AII-induced CYP11B2 transcription. However, telmisartan alone increased CYP11B2 transcription in the absence of AII. Telmisartan dose-dependently increased CYP11B2 transcription/mRNA expression and aldosterone secretion. Experiments using CYP11B2 promoter mutants indicated that the Ad5 element was responsible. Among transcription factors involved in the element, telmisartan significantly induced NGFIB/NURR1 expression. KN-93, a CaMK inhibitor, abrogated the telmisartan-mediated increase of CYP11B2 transcription/mRNA expression and NURR1 mRNA expression, but not NGFIB mRNA expression. NURR1 over-expression significantly augmented the telmisartan-mediated CYP11B2 transcription, while high-dose olmesartan did not affect it. Taken together, telmisartan may stimulate CYP11B2 transcription via NGFIB and the CaMK-mediated induction of NURR1 that activates the Ad5 element, independent of AII type 1 receptor.
What problem does this paper attempt to address?